Given the widespread role of STAT3 in various malignancies, TTI-101 has potential applications in a range of cancers. This includes breast cancer, lung cancer, prostate cancer, and glioblastoma. Clinical trials are currently exploring its efficacy and safety in these and other cancer types.
